Life Extension Magazine June 2005
By Dale Kiefer
By Dale Kiefer
Strong Evidence of Anti-Cancer Effects
Over the past 18 years, numerous medical and nutritional scientists have published research that validates and expands on the Wisconsin team’s groundbreaking work. Thanks to their efforts, we now know that CLA isomers, when added to the diets of laboratory animals, protect the animals against experimentally induced breast cancer, colon tumors, and skin cancer. These effects occurred regardless of whether the CLA was given during or after tumor initiation.3,5,24,25
Mounting evidence suggests that CLA’s anti-tumor activity comes primarily from the c9t11 isomer. The evidence for CLA’s ability to decrease the incidence, progression, tumor burden, and number of metastases in models of breast, prostate, skin, and colon cancer had grown so convincing by the mid-1990s that the National Academy of Sciences published a statement in 1996 declaring, “[CLA] is the only fatty acid shown unequivocally to inhibit carcinogenesis in experimental animals.”26
One of the animal models used in CLA research routinely serves as a model of a type of human breast cancer called ductal carcinoma in situ.5,24 The finding that CLA inhibits the formation of new tumors in rodents suggests that it may also reduce breast cancer metastasis in women. Confirming this expectation is an important new goal for oncology researchers, as the growth of secondary tumors (metastasis) is the leading cause of death among cancer patients.5
CLA also inhibits the growth of transplanted breast and prostate cancer cell lines in laboratory rodents.27,28 This effect was so dramatic that one research team was inspired to write, “Mice fed the CLA-supplemented diet displayed not only smaller local tumors than the regular diet-fed group, but also a drastic reduction in lung metastases.”28 Considerable evidence indicates that CLA inhibits the initiation stages of cancer, and research also shows that CLA inhibits the post-initiation and promotion phases of cancer growth.5 At least one study found that CLA inhibits the formation of secondary tumors in mice, even after cancerous mammary cells are seeded into the mice.29
In fact, recent evidence suggests that CLA fights cancer at every step in its progression, beginning with its initial development. By blocking cell cycle proteins that regulate the creation of new cells, CLA has been shown to stop runaway cell proliferation before aberrant (but benign) tissue transforms into far-from-benign cancer.5,30,31
In one experiment, researchers fed mice fed CLA for two weeks before inoculating them with aggressive human breast adenocarcinoma cells. Although the mice used in the study were bred for their inability to resist immune challenges, the CLA-treated mice developed 73% fewer local tumors by nine weeks after inoculation than did the control mice, which had not been pre-treated with dietary CLA. Furthermore, CLA dramatically inhibited the spread of breast cancer cells to lungs, peripheral blood, and bone marrow. The researchers concluded, “These results indicate the ability of dietary CLA to block both the local growth and systemic spread of human breast cancer via mechanisms independent of the host immune system.”27
Other research has shown that in a rodent model of human breast cancer, dietary exposure to CLA while mammary glands are maturing confers protection against the cancer. Even when CLA was withdrawn from the diet after mammary glands had matured, rats previously nourished with CLA continued to enjoy significant protection against mammary tumors. The mechanism by which CLA protects in this instance appears to be distinct from its anti-initiation activity.24,32
More recently, scientists in western New York gathered data from more than 1,100 women with confirmed breast cancer, as well as from about 2,000 cancer-free control patients. By assessing the subjects’ self-reported dietary intake of CLA, the researchers were able to look for statistical relationships between CLA intake and health status. Although no clear correlation appeared to exist between dietary intake of CLA and overall breast cancer risk, “a marginally significant reduction in risk of having an [estrogen receptor-negative] tumor” was reported among women with the highest intake of CLA. Regarding CLA, the researchers noted, “There may be associations with tumor biology at least among premenopausal women.”33
Recent reports indicate that CLA may also protect against breast and other types of cancer by inhibiting angiogenesis, the process by which tumors create a new blood supply network to obtain nutrients needed for growth. Halting or reversing angiogenesis is an anti-cancer strategy that has received intense attention by researchers from a variety of disciplines in recent years.34,35
CLA also promotes apoptosis (programmed cell death, or cellular suicide) of cancer cells.36-38 Cancer cells are adept at evading apoptosis, which accounts for much of their insidious nature. Apoptosis allows the body to remove damaged or potentially harmful cells in a way that minimizes waste and ameliorates damage to surrounding tissues. CLA evidently affects the functioning of immune system components involved in apoptosis.38
Recently, a research team in Argentina published a report on diet and the incidence of colon cancer among the local population. Argentineans consume a great deal of beef that is rich in saturated fat and cholesterol, while eating relatively little fish or dietary fiber. Fiber is generally recognized as protective against colon cancer, while heart-healthy omega-3 fatty acids, which are present primarily in seafood, may also help prevent cancer. Despite the Argentineans’ seemingly unhealthy eating habits, they do not succumb to colon cancer as commonly as might be expected.39
An analysis of epidemiological data revealed that high consumption of lean meats (less that 15% fat content) is actually associated with a significant reduction in the incidence of colon cancer among the populace. By contrast, high consumption of fatty meats, such as cold cuts and sausages, was associated with an increased risk of developing colon cancer. Because lean beef is a primary source of CLA, the researchers reasoned that CLA’s protective effects outweigh any presumed negative effects associated with the saturated fats and cholesterol in lean beef.39
Intentionally consuming more beef in order to obtain CLA is not a practical method of protecting one’s health. Most beef comes from cattle that are commercially fed and therefore have relatively little CLA. Numerous scientific studies indicate that those who over-consume beef have higher risks of common diseases.46-49 Those seeking to obtain CLA should consider supplements that provide standardized CLA concentrations.
1. Ha YL, Grimm NK, Pariza MW. Anticarcinogens from fried ground beef: heat-altered derivatives of linoleic acid. Carcinogenesis. 1987 Dec;8(12):1881-7.
2. Pariza MW, Park Y, Cook ME. Conjugated linoleic acid and the control of cancer and obesity. Toxicol Sci. 1999 Dec;52(2 Suppl):107-10.
3. Liew C, Schut HA, Chin SF, Pariza MW, Dashwood RH. Protection of conjugated linoleic acids against 2-amino-3- methylimidazo[4,5-f]quinoline-induced colon carcinogenesis in the F344 rat: a study of inhibitory mechanisms. Carcinogenesis. 1995 Dec;16(12):3037-43.
4. Belury MA. Dietary conjugated linoleic acid in health: physiological effects and mechanisms of action. Annu Rev Nutr. 2002;22:505-31.
5. Belury MA. Inhibition of carcinogenesis by conjugated linoleic acid: potential mechanisms of action. J Nutr. 2002 Oct;132(10):2995-8.
6. Belury MA, Vanden Heuvel JP. Protection against cancer and heart disease by CLA: potential mechanisms of action. Nutr Disease Update. 1997;1:58-63.
7. Scimeca JA. Cancer inhibition in animals. In: Yurawecz MP, Mossobo MM, Kramer JKG, Pariza MW, Nelson GJ, eds. Advances in Conjugated Linoleic Acid Research, Vol. 1. Champaign, IL: AOCS Press; 1999:420-43.
8. Pariza MW, Park Y, Cook ME. Mechanisms of action of conjugated linoleic acid: evidence and speculation. Proc Soc Exp Biol Med. 2000 Jan;223(1):8-13.
9. Lee KN, Kritchevsky D, Pariza MW. Conjugated linoleic acid and atherosclerosis in rabbits. Atherosclerosis. 1994 Jul;108(1):19-25.
10. Belury MA, Mahon A, Banni S. The conjugated linoleic acid (CLA) isomer, t10c12-CLA, is inversely associated with changes in body weight and serum leptin in subjects with type 2 diabetes mellitus. J Nutr. 2003 Jan;133(1):257S-60S.
11. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002 Oct 9;288(14):1723-7.
12. Hedley AA, Ogden CL, Johnson CL, et al. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA. 2004 Jun 16;291(23):2847-50.
13. Finkelstein EA, Fiebelkorn IC, Wang G. National medical spending attributable to overweight and obesity: how much, and who’s paying? Health Aff (Millwood.). 2003 Jan;Suppl Web ExclusivesW3-26.
14. Riserus U, Smedman A, Basu S, Vessby B. CLA and body weight regulation in humans. Lipids. 2003 Feb;38(2):133-7.
15. McCarty MF. Toward a wholly nutritional therapy for type 2 diabetes. Med Hypotheses. 2000 Mar;54(3):483-7.
16. Eyjolfson V, Spriet LL, Dyck DJ. Conjugated linoleic acid improves insulin sensitivity in young, sedentary humans. Med Sci Sports Exerc. 2004 May;36(5):814-20.
17. Zambell KL, Keim NL, Van Loan MD, et al. Conjugated linoleic acid supplementation in humans: effects on body composition and energy expenditure. Lipids. 2000 Jul;35(7):777-82.
18. Thom E, Wadstein J, Gudmundsen O. Conjugated linoleic acid reduces body fat in healthy exercising humans. J Int Med Res. 2001 Sep;29(5):392-6.
19. Blankson H, Stakkestad JA, Fagertun H, et al. Conjugated linoleic acid reduces body fat mass in overweight and obese humans. J Nutr. 2000 Dec;130(12):2943-8.
20. Smedman A, Vessby B. Conjugated linoleic acid supplementation in humans—metabolic effects. Lipids. 2001 Aug;36(8):773-81.
21. Whigham LD, O’Shea M, Mohede IC, Walaski HP, Atkinson RL. Safety profile of conjugated linoleic acid in a 12-month trial in obese humans. Food Chem Toxicol. 2004 Oct;42(10):1701-9.
22. Rohrmann S, Linseisen J, Becker N, et al. Cooking of meat and fish in Europe—results from the European Prospective Investigation into Cancer and Nutrition (EPIC). Eur J Clin Nutr. 2002 Dec;56(12):1216-30.
23. Felton JS, Knize MG, Salmon CP, Malfatti MA, Kulp KS. Human exposure to heterocyclic amine food mutagens/carcinogens: relevance to breast cancer. Environ Mol Mutagen. 2002;39(2-3):112-8.
24. Ip C, Chin SF, Scimeca JA, Pariza MW. Mammary cancer prevention by conjugated dienoic derivative of linoleic acid. Cancer Res. 1991 Nov 15;51(22):6118-24.
25. Belury MA, Nickel KP, Bird CE, Wu Y. Dietary conjugated linoleic acid modulation of phorbol ester skin tumor promotion. Nutr Cancer. 1996;26(2):149-57.
26. Available at: http://www.asas.org/JAS/symposia/proceedings/0938.pdf. Accessed February 16, 2005.
27. Visonneau S, Cesano A, Tepper SA, et al. Conjugated linoleic acid suppresses the growth of human breast adenocarcinoma cells in SCID mice. Anticancer Res. 1997 Mar;17(2A):969-73.
28. Cesano A, Visonneau S, Scimeca JA, Kritchevsky D, Santoli D. Opposite effects of linoleic acid and conjugated linoleic acid on human prostatic cancer in SCID mice. Anticancer Res. 1998 May;18(3A):1429-34.
29. Hubbard NE, Lim D, Summers L, Erickson KL. Reduction of murine mammary tumor metastasis by conjugated linoleic acid. Cancer Lett. 2000 Mar 13;150(1):93-100.
30. Ip C, Dong Y, Thompson HJ, Bauman DE, Ip MM. Control of rat mammary epithelium proliferation by conjugated linoleic acid. Nutr Cancer. 2001;39(2):233-8.
31. Futakuchi M, Cheng JL, Hirose M, et al. Inhibition of conjugated fatty acids derived from safflower or perilla oil of induction and development of mammary tumors in rats induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). Cancer Lett. 2002 Apr 25;178(2):131-9.
32. Ip C, Scimeca JA, Thompson H. Effect of timing and duration of dietary conjugated linoleic acid on mammary cancer prevention. Nutr Cancer. 1995;24(3):241-7.
33. McCann SE, Ip C, Ip MM, et al. Dietary intake of conjugated linoleic acids and risk of premenopausal and postmenopausal breast cancer, Western New York Exposures and Breast Cancer Study (WEB Study). Cancer Epidemiol Biomarkers Prev. 2004 Sep;13(9):1480-4.
34. Augustin HG. Translating angiogenesis research into the clinic: the challenges ahead. Br J Radiol. 2003;76 Spec No 1S3-10.
35. Masso-Welch PA, Zangani D, Ip C, et al. Inhibition of angiogenesis by the cancer chemopreventive agent conjugated linoleic acid. Cancer Res. 2002 Aug 1;62(15):4383-9.
36. Song HJ, Sneddon AA, Barker PA, et al. Conjugated linoleic acid inhibits proliferation and modulates protein kinase C isoforms in human prostate cancer cells. Nutr Cancer. 2004;49(1):100-8.
37. Liu J, Chen B, Yang Y, Wang X. Effect of apoptosis in human mammary cancer (MCF-7) cells induced by cis9, t11-conjugated linoleic acid. Wei Sheng Yan Jiu. 2004 Jan;33(1):58-62.
38. Maggiora M, Bologna M, Ceru MP, et al. An overview of the effect of linoleic and conjugated-linoleic acids on the growth of several human tumor cell lines. Int J Cancer. 2004 Dec 20;112(6):909-19.
39. Eynard AR, Lopez CB. Conjugated linoleic acid (CLA) versus saturated fats/cholesterol: their proportion in fatty and lean meats may affect the risk of developing colon cancer. Lipids Health Dis. 2003 Aug 29;2(1):6.
40. Yamashita K, Iizuka Y, Imai T, Namiki M. Sesame seed and its lignans produce marked enhancement of vitamin E activity in rats fed a low alpha-tocopherol diet. Lipids. 1995 Dec;30(11):1019-28.
41. Sankar D, Sambandam G, Rao MR, Pugalendi KV. Impact of sesame oil on nifedipine in modulating oxidative stress and electrolytes in hypertensive patients. Asia Pac J Clin Nutr. 2004;13(Suppl);S107.
42. Kang MH, Kawai Y, Naito M, Osawa T. Dietary defatted sesame flour decreases susceptibility to oxidative stress in hypercholesterolemic rabbits. J Nutr. 1999 Nov;129(10):1885-90.
43. Ashakumary L, Rouyer I, Takahashi Y, et al. Sesamin, a sesame lignan, is a potent inducer of hepatic fatty acid oxidation in the rat. Metabolism. 1999 Oct;48(10):1303-13.
44. Sugano M, Akahoshi A, Koba K, et al. Dietary manipulation of body fat-reducing potential of conjugated linoleic acid in rats. Biosci Biotechnol Biochem. 2001 Nov;65(11):2535-41.
45. Sakono M, Yuji K, Miyanaga F, et al. Combined effect of dietary conjugated linoleic acid and sesamin triacylglycerol and ketone body production in rat liver. J Nutr Sci Vitaminol. 2002 Oct;48(5):405-9.
46. Chao A, Thun MJ, Connell CJ, et al. Meat consumption and risk of colorectal cancer. JAMA. 2005 Jan 12;293(2):172-82.
47. Larsson SC, Rafter J, Holmberg L, Bergkvist L, Wolk A. Red meat consumption and risk of cancers of the proximal colon, distal colon, and rectum: the Swedish Mammography Cohort. Int J Cancer. 2005 Feb 20;113(5):829-34.
48. Hu FB, Rimm EB, Stampfer MJ, Ascherio A, Spiegelman D, Willett WC. Prospective study in major dietary patterns and risk of coronary heart disease in men. Am J Clin Nutr. 2000 Oct;72(4):912-21.
49. Pattison DJ, Symmons DP, Lunt M, et al. Dietary risk factors for the development of inflammatory polyarthritis: evidence for a role of high level of red meat consumption. Arthritis Rheum. 2004 Dec;50(12):3804-12.